We showcase how the Nordic Bioscience Protein Fingerprint neo-epitope technology provides serological quantification for Extracellular Matrix (ECM) remodeling.
Promising outlook for prognostic biomarkers related to HFpEF
KKR's investment will support Nordic Bioscience with its ambitious growth goals: Global expansion of R&D services, diagnostics platform, leading patent portfolio, and drug development.
Search and find publications that we have published.
Please don't hesitate to contact us if you have any questions or other inquiries.
